Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASM-001
- Development stage
- Preclinical
- Lead developer
- Guangzhou Aisima Bio-pharmaceutical Technology
- Modality
- Small Molecules
01
Overview
ASM-001 is a preclinical-stage small molecule therapeutic candidate being developed by Guangzhou Aisima Bio-pharmaceutical Technology (ExcelMab) for the potential treatment of cancer. While Guangzhou Aisima Bio-pharmaceutical Technology primarily focuses on its proprietary ExMab® bispecific antibody platform, ASM-001 represents a small molecule asset within its early-stage oncology pipeline.
Beyond the preview
Go deeper on ASM-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASM-001.